DENTSPLY SIRONA Reports Strong Second Quarter Earnings for FY2023
August 12, 2023
☀️Earnings Overview
On August 2 2023, DENTSPLY SIRONA ($NASDAQ:XRAY) reported their earnings results for the second quarter of FY2023, which ended on June 30 2023. Revenue for the quarter was USD 1028.0 million, 0.5% higher than the same period in the previous year, and net income was USD 86.0 million, a 17.8% increase from the prior year.
Market Price
The company’s stock opened at $41.1 and closed at $40.7, down 1.7% from the last closing price of 41.4. The second quarter results show that the company is on track to reach its projected growth targets. This was mainly driven by its higher product mix of dental implants and higher demand from China and other emerging markets. The company remains focused on its global expansion strategies and is confident that it will be able to deliver solid results in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dentsply Sirona. More…
| Total Revenues | Net Income | Net Margin |
| 3.94k | -1.02k | 3.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dentsply Sirona. More…
| Operations | Investing | Financing |
| 334 | -122 | -237 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dentsply Sirona. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.65k | 3.95k | 17.14 |
Key Ratios Snapshot
Some of the financial key ratios for Dentsply Sirona are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.6% | 6.0% | -29.0% |
| FCF Margin | ROE | ROA |
| 5.0% | -19.6% | -9.3% |
Analysis
As GoodWhale, we have performed an analysis of DENTSPLY SIRONA‘s fundamentals and found a high health score of 7/10 on our Star Chart. This indicates that DENTSPLY SIRONA is capable of paying off debt and funding future operations. Our analysis classified DENTSPLY SIRONA as a ‘cow’, meaning it has had a consistent and sustainable track record of paying out dividends. From our analysis, DENTSPLY SIRONA is strong in dividend and profitability, but weak in asset and growth. This suggests that investors who are looking for a high dividend yield and reliable profits may find this company appealing. Investors seeking higher growth should look elsewhere. More…
Peers
In the competitive world of dental equipment manufacturers, Dentsply Sirona Inc. has held its own against some tough competitors. Edwards Lifesciences Corp, Escalon Medical Corp, and Medistim ASA are all companies that produce dental equipment and supplies that compete with Dentsply Sirona Inc.
– Edwards Lifesciences Corp ($NYSE:EW)
Edwards Lifesciences Corp is a medical technology company that specializes in products and technologies for the treatment of cardiovascular diseases. The company’s market capitalization is $45.45 billion as of 2022, and its return on equity is 18.9%. Edwards Lifesciences is headquartered in Irvine, California, and has operations in more than 75 countries worldwide.
– Escalon Medical Corp ($OTCPK:ESMC)
Escalon Medical Corp is a medical device company that manufactures and markets products for the ophthalmology, optometry, and veterinary markets worldwide. It has a market cap of 800.11k as of 2022 and a return on equity of 1.57%. The company’s products include ophthalmic surgical instruments, intraocular lenses, contact lenses, and disposables.
– Medistim ASA ($BER:MD1)
Medistim ASA is a Norwegian medical device company that develops, manufactures, and markets products for use in cardiac and vascular surgery. The company has a market capitalization of 455.95 million as of 2022 and a return on equity of 24.86%. Medistim’s products are used in a variety of procedures, including coronary artery bypass graft surgery, valve replacement surgery, and endovascular surgery. The company’s products are sold in over 50 countries worldwide.
Summary
DENTSPLY SIRONA reported strong earnings results for the second quarter of their FY2023, with total revenue of USD 1028.0 million, up 0.5% from the prior year and net income of USD 86.0 million, up 17.8%. This favorable performance signals a healthy business outlook for DENTSPLY SIRONA and is likely to be an attractive investment opportunity for investors. With strong sales growth, improved profitability, and a robust portfolio of products, investors should consider diversifying their portfolios with shares in DENTSPLY SIRONA.
Related Posts
Recent Posts
